Novozymes (NSIS N) Stock Overview

Produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. More details

NSIS N fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	3/6
Financial Health	4/6
Dividends	3/6

Rewards

Earnings are forecast to grow 19.52% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Has a high level of debt

NSIS N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Novozymes A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novozymes
Historical stock prices
Current Share Price	DKK 911.11
52 Week High	DKK 938.65
52 Week Low	DKK 730.70
Beta	0.48
1 Month Change	0%
3 Month Change	n/a
1 Year Change	0.47%
3 Year Change	-31.10%
5 Year Change	0.96%
Change since IPO	15.79%

Recent updates

Shareholder Returns

	NSIS N	MX Chemicals	MX Market
7D	0%	2.7%	3.2%
1Y	0.5%	25.9%	25.3%

Return vs Industry: NSIS N exceeded the MX Chemicals industry which returned -8.5% over the past year.

Return vs Market: NSIS N underperformed the MX Market which returned 4.2% over the past year.

Price Volatility

Is NSIS N's price volatile compared to industry and market?
NSIS N volatility
NSIS N Average Weekly Movement	n/a
Chemicals Industry Average Movement	5.2%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.0%
10% least volatile stocks in MX Market	2.5%

Stable Share Price: NSIS N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NSIS N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1925	6,577	Ester Baiget	www.novonesis.com

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novozymes A/S Fundamentals Summary

How do Novozymes's earnings and revenue compare to its market cap?
NSIS N fundamental statistics
Market cap	Mex$419.73b
Earnings (TTM)	Mex$7.22b
Revenue (TTM)	Mex$42.74b

58.1x

P/E Ratio

9.8x

P/S Ratio

Is NSIS N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NSIS N income statement (TTM)
Revenue	DKK 17.90b
Cost of Revenue	DKK 8.18b
Gross Profit	DKK 9.72b
Other Expenses	DKK 6.70b
Earnings	DKK 3.02b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 03, 2024

Earnings per share (EPS)	6.51
Gross Margin	54.32%
Net Profit Margin	16.89%
Debt/Equity Ratio	51.6%

How did NSIS N perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

88%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/04/10 20:03
End of Day Share Price	2024/01/12 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novozymes A/S is covered by 33 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sebastian Satz	Barclays
Cezara Lozneanu	Barclays
Alexander Sloane	Barclays

Novozymes (NSIS N) Stock Overview

Rewards

Risk Analysis

Novozymes A/S Competitors

Industrias Peñoles. de

CEMEX. de

Grupo México. de

Corporación Moctezuma. de

Price History & Performance

Recent News & Updates

Novozymes A/S Revises Earnings Guidance for the Year 2025

Novonesis A/S Approves Interim Dividend for First Half of 2025

Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Recent updates

Novozymes A/S Revises Earnings Guidance for the Year 2025

Novonesis A/S Approves Interim Dividend for First Half of 2025

Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Novonesis A/S Announces Board Changes

Novonesis A/S Proposes Dividend, Payable on April 8, 2025

Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025

Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Shareholder Returns

Price Volatility

About the Company

Novozymes A/S Fundamentals Summary